Enhanced half-life and antitumor activity of interleukin-15 through genetic fusion of a serum albumin-specific protein binder

[Display omitted] Human interleukin-15 (hIL-15) has attracted a considerable attention as a promising cancer immunotherapeutic due to its function to directly stimulate the proliferation and cytotoxic activity of NK and T cells. Nevertheless, a relatively short half-life of hIL-15 requires repeated...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of pharmaceutics 2022-09, Vol.625, p.122059-122059, Article 122059
Hauptverfasser:	Kim, Dasom, Park, Jin-Ho, Kim, Tae-Yoon, Kim, Dong-Gun, Byun, June-Ho, Kim, Hak-Sung
Format:	Artikel
Sprache:	eng
Schlagworte:	Genetic fusion Half-life Immune cells Immunotherapy Interleukin 15 Protein binder
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!